Format

Send to

Choose Destination
See comment in PubMed Commons below
Head Neck. 2011 Feb;33(2):286-8. doi: 10.1002/hed.21299.

Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck.

Author information

1
Radiation Oncology, Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. kim18@umdnj.edu

Abstract

BACKGROUND:

Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy.

METHODS:

We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m(2) loading dose and a 250 mg/m(2) weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues.

RESULTS:

The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response.

CONCLUSIONS:

Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile.

PMID:
19953623
DOI:
10.1002/hed.21299
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center